RJA
AMPE

Raymond James & Associates’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Raymond James & Associates’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-238
Closed -$4K – 4143
2022
Q3 		$4K Buy
238
+17
+8% +$595 ﹤0.01% 3901
2022
Q2 		$11K Sell
221
-3
-1% -$223 ﹤0.01% 3934
2022
Q1 		$32K Hold
224
– – ﹤0.01% 3956
2021
Q4 		$38K Sell
224
-492
-69% -$183K ﹤0.01% 3981
2021
Q3 		$357K Sell
716
-4
-0.6% -$1.85K ﹤0.01% 3293
2021
Q2 		$361K Buy
720
+79
+12% +$42.4K ﹤0.01% 3307
2021
Q1 		$325K Sell
641
-2
-0.3% -$1.03K ﹤0.01% 3307
2020
Q4 		$307K Buy
643
+5
+0.8% +$1.64K ﹤0.01% 3111
2020
Q3 		$183K Sell
638
-10
-2% -$2.48K ﹤0.01% 3249
2020
Q2 		$124K Sell
648
-17
-3% -$2.83K ﹤0.01% 3245
2020
Q1 		$83K Buy
665
+3
+0.5% +$543 ﹤0.01% 3245
2019
Q4 		$116K Buy
662
+25
+4% +$3.23K ﹤0.01% 3453
2019
Q3 		$96K Buy
637
+167
+36% +$22.3K ﹤0.01% 3393
2019
Q2 		$55K Buy
470
+50
+12% +$7.92K ﹤0.01% 3492
2019
Q1 		$71K Buy
420
+367
+692% +$62.9K ﹤0.01% 3442
2018
Q4 		$6K Sell
53
-208
-80% -$31.9K ﹤0.01% 3488
2018
Q3 		$40K Buy
261
+56
+27% +$23.4K ﹤0.01% 3504
2018
Q2 		$135K Buy
205
+8
+4% +$5.99K ﹤0.01% 3353
2018
Q1 		$201K Buy
197
+85
+76% +$71.2K ﹤0.01% 3132
2017
Q4 		$137K Buy
+112
New +$52.7K ﹤0.01% 3157
2017
Q3 		– Sell
-53
Closed -$8K – 3517
2017
Q2 		$8K Hold
53
– – ﹤0.01% 3304
2017
Q1 		$13K Sell
53
-2
-4% -$538 ﹤0.01% 3231
2016
Q4 		$15K Buy
55
+14
+34% +$3.33K ﹤0.01% 3165
2016
Q3 		$9K Buy
+41
New +$11.5K ﹤0.01% 3176

Other funds holding AMPE

CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
ARG
Advisory Resource Group Tulsa, Oklahoma $665M AUM 29.27% 1-Year Est. Return
CCMW
Cypress Capital Management (Wyoming) Sheridan, Wyoming $108M AUM 54.47% 1-Year Est. Return

Raymond James & Associates's AMPE Position: Q4 2022 in Review

Raymond James & Associates sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q4 2022, closing a stake of 238 shares — an estimated $4K sold.

Raymond James & Associates first reported a position in AMPE in Q3 2016 and held it in 24 quarters. The position peaked at $361K in Q2 2021. 32 funds tracked by Wall St. Rank hold AMPE as of Q4 2022.

  • Raymond James & Associates reported no remaining Ampio Pharmaceuticals Inc. position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 238 Ampio Pharmaceuticals Inc. shares in Q4 2022, an estimated $4K.
  • Raymond James & Associates first reported a position in Ampio Pharmaceuticals Inc. in Q3 2016 and held it in 24 quarters.
  • Raymond James & Associates's Ampio Pharmaceuticals Inc. position peaked at $361K in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.